Pune-headquartered Brinton Pharmaceuticals has received Drugs Controller General of India's (DCGI) approval to sell antiviral drug favipiravir under the brand name 'Faviton' for treatment of COVID-19 patients. The drug will be available in 200 mg tablets and will be sold at ₹59 per tablet. Favipiravir is an effective treatment option in the management of mild-to-moderate COVID-19, Brinton said.